The board of directors granted an aggregate of 35,890 warrants to certain employees under the Company’s Articles of Association. Each warrant confers the right to subscribe for one ordinary share with an exercise price equal to US $223.21 per share, reflecting the closing price on the grant date. Vesting is structured such that 25% vests on the one-year anniversary, while the remaining 75% vests monthly at a rate of 1/36th thereafter, subject to continued service and potential acceleration upon exit events. Following this issuance, warrants for an additional 1,459,173 shares remain available for future grants. Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases.
